| Gisselbrecht, Christian |
NCT00005584: Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Hodgkin's Lymphoma |
|
|
| Active, not recruiting | 3 | 1649 | Europe | bleomycin sulfate, ABVD regimen, BEACOPP regimen, epirubicin hydrochloride, prednisone, vinblastine sulfate, radiation therapy | European Organisation for Research and Treatment of Cancer - EORTC, Lymphoma Study Association, UNICANCER | Lymphoma | 05/04 | | | |
| Molina, Jean-Michel |
DOXYVAC, NCT04597424: Combined Prevention of Sexually Transmitted Infections (STIs) in Men Who Have Sex With Men and Using Oral Tenofovir Disoproxil Fumarate/ Emtricitabine (TDF/FTC) for HIV Pre-Exposure Prophylaxis (PrEP) |
|
|
| Completed | 3 | 556 | Europe | Experimental: doxycycline, Bexsero® vaccine | ANRS, Emerging Infectious Diseases | Unsafe Sex, Risk-Taking | 02/23 | 04/24 | | |
| Not yet recruiting | 3 | 322 | Europe | Cabotegravir Tablets, for oral use., VOCABRIA, Cabotegravir Extended-Release Injectable Suspension, for intramuscular use., APRETUDE, Tenofovir disoproxil/Emtricitabine 300mg/200mg fixed-dose combination tablets, for oral use, TRUVADA, Rectal Biopsies | ANRS, Emerging Infectious Diseases | Prevention | 10/25 | 10/26 | | |
NCT03696160: The Late Presenter Treatment Optimisation Study |
|
|
| Completed | 3 | 447 | Europe | Biktarvy, Symtuza | NEAT ID Foundation, Gilead Sciences, Janssen Pharmaceuticals | HIV/AIDS | 06/24 | 06/24 | | |
VOLITION, NCT05917509: A Study to Evaluate the Efficacy, Safety, Participant Choice and Preference of an Oral Once-daily Regimen or a Long-acting Injectable Regimen Every Two Months for Treatment of Human Immunodeficiency Virus (HIV-1) in Adults Who Have Not Previously Taken Antiretroviral Therapy |
|
|
| Active, not recruiting | 3 | 171 | Europe, Canada, US, RoW | DTG/3TC, Dovato, Cabotegravir (CAB) LA, Vocabria, Rilpivirine (RPV) LA, Rekambys | ViiV Healthcare, GlaxoSmithKline, PPD | HIV Infections | 08/25 | 08/26 | | |
OPTICOV, NCT05587894: OPtimisation of Antiviral Therapy in Immunocompromised COVID-19 Patients: a Randomized Factorial Controlled Strategy Trial |
|
|
| Recruiting | 2 | 256 | Europe | Paxlovid 5 days, Nirmatrevlir/ritonavir, Paxlovid 10 days, Veklury, remdesivir | ANRS, Emerging Infectious Diseases, University Hospital, Geneva | COVID-19, Immunodeficiency | 03/25 | 05/25 | | |
RHIVIERA-02, NCT05300035: Phase II Trial of ART + Dual bNAbs vs. ART + Placebo During Primary HIV-1 Infection-impact on Post-ART Control |
|
|
| Recruiting | 2 | 69 | Europe | Recombinant human monoclonal antibody (bNAbs), 10-1074-LS and 3BNC117-LS, Placebo, Saline solution | ANRS, Emerging Infectious Diseases, Rockefeller University, Institut Pasteur | HIV/AIDS and Infections | 12/26 | 12/28 | | |
| Recruiting | N/A | 3257 | Europe | PrEP with Truvada®, Tenofovir Disoproxil Fumarate/Emtricitabine (TDF/FTC) | ANRS, Emerging Infectious Diseases | HIV Infections | 05/24 | 10/24 | | |
| Not yet recruiting | N/A | 300 | Europe | Collection of data from the patient's medical file | Assistance Publique - Hôpitaux de Paris | Haemophilus Influenzae Pneumonia | 05/25 | 05/25 | | |
NCT05482854: Assessment of HIV Remission Upon cART Interruption in Early Treated Individuals Carrying the MHC B35/53Bw4TTC2 Genotype |
|
|
| Recruiting | N/A | 50 | Europe | Analytical Treatment Interruption (ATI) | ANRS, Emerging Infectious Diseases | HIV Infections | 12/24 | 07/25 | | |
DOXY-PK, NCT06007534: Pharmacokinetic Characterization of a Single 200 mg Dose of Doxycycline in Post-exposure Prophylaxis (PEP) of Sexually Transmitted Infections in Different Biological Compartments |
|
|
| Recruiting | N/A | 25 | Europe | Samples | Assistance Publique - Hôpitaux de Paris | Post-exposure Prophylaxis, Sexually Transmitted Diseases, Doxycycline | 04/25 | 04/25 | | |
| Recruiting | N/A | 2200 | Europe, RoW | Data collection | ANRS, Emerging Infectious Diseases | Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) | 04/21 | 05/21 | | |
| Recruiting | N/A | 1185 | Europe | Antiretroviral | French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS) | HIV-2 Infection | 09/22 | 09/22 | | |
| Oksenhendler, Eric |
| Recruiting | N/A | 1000 | US | | University of Pennsylvania, EUSA Pharma, Inc., Castleman Disease Collaborative Network, Food and Drug Administration (FDA) | Castleman Disease, Castleman's Disease, Giant Lymph Node Hyperplasia, Angiofollicular Lymph Hyperplasia, Angiofollicular Lymph Node Hyperplasia, Angiofollicular Lymphoid Hyperplasia, GLNH, Hyperplasia, Giant Lymph Node, Lymph Node Hyperplasia, Giant | 09/26 | 09/26 | | |
| Dombret, Hervé |
GRAAPH2014, NCT02611492: A Phase III Randomized Trial of the Reduction of Chemotherapy in Philadelphia Chromosome-positive ALL of Young Adults |
|
|
| Recruiting | 3 | 265 | Europe | Nilotinib, Methotrexate, Aracytine (Ara C), Granulocyte Colony-Stimulating Factor (G-CSF), Depomedrol, Dexamethasone, Vincristine, Imatinib, 6 Mercaptopurine (6MP) | Assistance Publique - Hôpitaux de Paris | Philadelphia Chromosome Positive Adult Acute Lymphoblastic Leukemia | 12/20 | 12/25 | | |
| Recruiting | 2 | 275 | Europe | nelarabine | Assistance Publique - Hôpitaux de Paris | T-cell Adult Acute Lymphoblastic Leukemia | 12/20 | 12/25 | | |
GRAALL-2014/B, NCT02617004: Multicenter Trial Treatment of Philadelphia Chromosome Negative B-cell Acute Lymphoblastic Leukemia of Young Adults |
|
|
| Recruiting | N/A | 500 | Europe | | Assistance Publique - Hôpitaux de Paris | Philadelphia Chromosome Negative Adult B-cell Acute Lymphoblastic Leukemia | 12/20 | 12/25 | | |
ALFAPPP, NCT04777916: Prospective Non-interventional Study of Adult Patients With Acute Myeloid Leukemia (AML) |
|
|
| Recruiting | N/A | 2500 | Europe | | Acute Leukemia French Association | Acute Myeloid Leukemia (AML) | 04/32 | 04/46 | | |
| Recruiting | N/A | 3000 | Europe | Biobanking | Assistance Publique - Hôpitaux de Paris | Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, High-risk Myelodysplastic Syndrome, Secondary Myelofibrosis in Myeloproliferative Disease, Myeloproliferative Neoplasm, Unclassifiable | 03/42 | 03/42 | | |
| Thieblemont, Catherine |
MorningLyte, NCT06284122: Study of Mosunetuzumab Plus Lenalidomide Compared to Anti-CD20 Anti-body + Chemotherapy in Follicular Lymphoma FLIPI2-5 |
|
|
| Recruiting | 3 | 790 | Europe | Mosunetuzumab, Lenalidomide, Rituximab, Obinutuzumab, Cyclophosphamide, Doxorubicin, Vincristin, Prednisone, Bendamustin | The Lymphoma Academic Research Organisation, Lymphoma Study Association, Swiss Group for Clinical Cancer Research, Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea | Follicular Lymphoma | 11/28 | 04/34 | | |
BRUIN CLL-322, NCT04965493 / 2021-000043-49: A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) |
|
|
| Recruiting | 3 | 600 | Europe, Canada, Japan, US, RoW | Pirtobrutinib, LOXO-305, LY3527727, Venetoclax, Venclexta, Venclyxto, Rituximab, Rituxan, MabThera, Truxima, Riabni, Ruxience | Loxo Oncology, Inc., Eli Lilly and Company | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 04/26 | 01/27 | | |
SYMPHONY-1, NCT04224493 / 2019-003333-42: A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma. |
|
|
| Recruiting | 3 | 612 | Europe, Canada, US, RoW | Tazemetostat, EPZ-6438, IPN60200, Placebo oral tablet, Lenalidomide, Rituximab | Epizyme, Inc. | Relapsed/Refractory Follicular Lymphoma, Follicular Lymphoma, Refractory Follicular Lymphoma | 03/26 | 03/29 | | |
|
|
|
|
|
|
|
MARSUN, NCT06006117: Mosunetuzumab-Lenalidomide Versus Investigator Choices in Patients With Relapsed or Refractory Marginal Zone Lymphoma |
|
|
| Recruiting | 3 | 260 | Europe | Mosunetuzumab + Lenalidomide, Arm 1, - Rituximab + Lenalidomide (28-days cycles, Arm 2, - Rituximab + Bendamustine (28-days cycles), Arm 3, - Rituximab + CHOP (21-days cycles), Arm 4 | The Lymphoma Academic Research Organisation | Marginal Zone Lymphoma | 09/27 | 09/32 | | |
RITZ, NCT05735834: Comparison Between Rituximab Plus Zanubrutinib Versus Rituximab Monotherapy in Untreated SMZL Patients |
|
|
| Recruiting | 3 | 120 | Europe | Rituximab, Truxima, Zanubrutinib, Brukinsa | International Extranodal Lymphoma Study Group (IELSG) | Splenic Marginal Zone Lymphoma | 05/29 | 05/29 | | |
ALYCANTE, NCT04531046: Axi-Cel as a 2nd Line Therapy in Patients With Relapsed/Refractory Aggressive B Lymphoma Ineligible to Autologous Stem Cell Transplantation |
|
|
| Active, not recruiting | 2 | 62 | Europe | axicabtagene ciloleucel, axi-cel | The Lymphoma Academic Research Organisation | B-Cell Lymphoma Refractory, B-cell Lymphoma Recurrent | 04/22 | 06/26 | | |
| Active, not recruiting | 2 | 67 | Europe | Obinutuzumab, gazyva, RO7082859, glofitamab | The Lymphoma Academic Research Organisation | Diffuse Large B-Cell Lymphoma Refractory, Refractory Indolent Adult Non-Hodgkin Lymphoma, Refractory Transformed B-cell Non-Hodgkin Lymphoma, Refractory Primary Mediastinal Large B-Cell Cell Lymphoma, Refractory Mantle Cell Lymphoma | 01/23 | 03/26 | | |
| Active, not recruiting | 2 | 168 | Europe, RoW | MB-CART2019.1, R-GemOx or BR plus polatuzumab vedotin, Rituximab, Gemcitabine, Oxaliplatin, Polatuzumab vedotin, Bendamustine, Rituximab | Miltenyi Biomedicine GmbH, ICON plc | Diffuse Large B-cell Lymphoma | 12/24 | 07/27 | | |
NCT06271057: Golcadomide Post-CAR T-cell in R/R Aggressive Large B-cell Lymphoma Patients With High Risk of Relapse |
|
|
| Recruiting | 2 | 65 | Europe | golcadomide, BMS-986369, CC-99282 | The Lymphoma Academic Research Organisation, Lymphoma Study Association | Diffuse Large B-cell Lymphoma Refractory, Refractory Primary Mediastinal Large B-Cell Lymphoma, Refractory Transformed B-cell Non-Hodgkin Lymphoma, Refractory High Grade B-Cell Lymphoma | 01/26 | 10/27 | | |
| Active, not recruiting | 2 | 175 | Europe | Ibrutinib, Rituximab | International Extranodal Lymphoma Study Group (IELSG), Janssen-Cilag AG, F. Hoffmann La Roche Ltd, Janssen Pharmaceutica NV | Marginal Zone Lymphoma, Nodal Marginal Zone Lymphoma, Splenic Marginal Zone Lymphoma | 06/27 | 06/27 | | |
Relyage, NCT04113226: Assessment of Survival and Autonomy With Rituximab Plus Chemotherapy or Rituximab Plus Lenalidomide for Elderly Patients With Relapsed Diffuse Large B-cell Lymphoma |
|
|
| Recruiting | 2 | 114 | Europe | Rituximab, Lenalidomide 20 MG, Comprehensive Geriatric Assessment (CGA), Activities of daily living (ADL) scale | Centre Hospitalier Universitaire, Amiens, cimiez hospital Nice, Institut Bergonié, groupe hospitalier public sud de l'oise, Henri Mondor University Hospital, Centre Henri Becquerel, Hôpital Charles Foix, Saint-Louis Hospital, Paris, France | Chemotherapy, Diffuse Large B-Cell Lymphoma (DLBCL), Nos, Elderly | 12/24 | 12/24 | | |
| Recruiting | 2 | 56 | Europe | Lacutamab, Gemcitabine, Oxaliplatine | The Lymphoma Academic Research Organisation, Innate Pharma | Peripheral T Cell Lymphoma, Relapse/Recurrence | 01/25 | 01/27 | | |
|
| Recruiting | 2 | 180 | Europe, Japan, US, RoW | Epcoritamab, GEN3013, DuoBody®-CD3×CD20, EPKINLY™, Lenalidomide, Revlimid® | Genmab, AbbVie | Diffuse Large B-Cell Lymphoma | 01/26 | 03/27 | | |
OASIS-II, NCT04802590: Study of Ibrutinib + CD20 Antibody and Venetoclax in Patients With Untreated Mantle Cell Lymphoma |
|
|
| Recruiting | 2 | 194 | Europe | Ibrutinib 560 mg, Venetoclax 10 MG Oral Tablet [Venclexta], Venetoclax 50 MG Oral Tablet [Venclexta], Venetoclax 100 MG Oral Tablet [Venclexta] | The Lymphoma Academic Research Organisation, Institute of Cancer Research, United Kingdom | Mantle Cell Lymphoma | 03/26 | 09/31 | | |
| Recruiting | N/A | 350 | Europe | | International Extranodal Lymphoma Study Group (IELSG) | Marginal Zone Lymphoma | 12/25 | 12/25 | | |
ALK-OBS, NCT03603847: Prospective Study of the Prognostic Value of New Markers in Adults With ALK-positive Large Anaplastic Lymphoma |
|
|
| Completed | N/A | 41 | Europe | | The Lymphoma Academic Research Organisation, Hôpital Necker-Enfants Malades, Fondation ARC, Pfizer, Takeda | Anaplastic Large Cell Lymphoma, ALK-Positive | 06/23 | 06/23 | | |
THEMIS, NCT05350826: Evaluation of the Ambulatory Medical Assistance Nurse Program in Chronic Lymphocytic Leukemia |
|
|
| Recruiting | N/A | 450 | Europe | Ambulatory medical assistance | University Hospital, Toulouse | Chronic Lymphoid Leukemia | 07/25 | 07/25 | | |
| Recruiting | N/A | 6000 | Europe | Real-life epidemiological platform of lymphoma in France | Hospices Civils de Lyon, The Lymphoma Academic Research Organisation | Diffuse Large B Lymphoma (DLBCL), Follicular Lymphoma (FL), Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL), T-cell Lymphoma (T-NHL), Hodgkin's Lymphoma (HL), Burkitt Lymphoma (BL)) | 11/27 | 11/27 | | |
| Recruiting | N/A | 1800 | Europe | | The Lymphoma Academic Research Organisation, Gilead Sciences, Novartis | Hematopathology Eligible or CAR-t Cell Treatment | 12/38 | 12/38 | | |
NCT05700149: Integrated Molecular and Clinical Profiling to Improve Disease Characterization and Outcome Prediction in Nodal Marginal Zone Lymphoma |
|
|
| Recruiting | N/A | 300 | Europe, US, RoW | | International Extranodal Lymphoma Study Group (IELSG) | Nodal Marginal Zone Lymphoma | 12/26 | 12/26 | | |
| Rousselot, Philippe |
| Active, not recruiting | 3 | 245 | Europe, Canada, Japan, US, RoW | Ponatinib, Iclusig, Imatinib, Gleevec, Vincristine, Dexamethasone, Cytarabine, Methotrexate, Prednisone | Takeda | Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL) | 08/22 | 07/27 | | |
|
|
| Recruiting | 3 | 550 | Europe, Canada, US, RoW | Tamibarotene, SY-1425, Placebo, Azacitidine | Syros Pharmaceuticals | Myelodysplastic Syndromes | 11/24 | 02/29 | | |
| Recruiting | 3 | 322 | Europe, Canada, US | Crenolanib, Crenolanib besylate, Cytarabine, Mitoxantrone, Placebo Oral Tablet, Fludarabine, Idarubicin, G-CSF | Arog Pharmaceuticals, Inc. | Relapsed/Refractory Acute Myeloid Leukemia With FLT3 Activating Mutations | 10/24 | 10/24 | | |
NCT05753384: Discontinuation of TyrosIne Kinase Inhibitors (TKI) in Chronic Myeloid Leukemia (CML) and Impact on the Immune System |
|
|
| Recruiting | 3 | 140 | Europe | treatment of TKI in CML | Poitiers University Hospital | Tyrosine Kinase Inhibitors, Chronic Myeloid Leukemia | 12/28 | 12/29 | | |
BIG-1, NCT02416388: Study to Improve OS in 18 to 60 Year-old Patients, Comparing Daunorubicin Versus High Dose Idarubicin Induction Regimens, High Dose Versus Intermediate Dose Cytarabine Consolidation Regimens, and Standard Versus MMF Prophylaxis of GvHD in Allografted Patients in First CR |
|
|
| Recruiting | 2/3 | 3100 | Europe | Idarubicin, Daunorubicin, HD Cytarabine, Cyclosporine, Methotrexate, Mycophenolic acid (MPA), vosaroxin, ID cytarabine, Dexamethasone, Venetoclax | University Hospital, Angers | Acute Myeloid Leukemia (AML) | 07/25 | 01/32 | | |
| Not yet recruiting | 2 | 99 | Europe | Experimental drug | Versailles Hospital | SARS Virus | 12/20 | 12/21 | | |
PONAZA, NCT03895671: : A COMBINATION OF PONATINIB AND 5-AZACITIDINE IN CHRONIC MYELOGENOUS LEUKAEMIA IN ACCELERATED PHASE OR IN MYELOID BLAST CRISIS |
|
|
| Recruiting | 2 | 40 | Europe | Ponatinib, Azacitidine | Versailles Hospital | CHRONIC MYELOGENOUS LEUKAEMIA IN ACCELERATED PHASE, CHRONIC MYELOGENOUS LEUKAEMIA IN MYELOID BLAST CRISIS | 12/23 | 12/24 | | |
| Active, not recruiting | 2 | 95 | Europe, US | Tamibarotene, Venetoclax, Venclexta, Azacitidine, Vidaza | Syros Pharmaceuticals | Acute Myeloid Leukemia | 04/28 | 04/28 | | |
ACTIW, NCT02767063: Therapies in Combination or Sequentially With Tyrosine Kinase Inhibitors (TKIs) in Chronic Phase Chronic Myelogenous Leukemia Patients in CCR |
|
|
| Recruiting | 1/2 | 100 | Europe | Pioglitazone, Avelumab | Versailles Hospital | Leukemia, Myeloid, Chronic-Phase | 11/22 | 06/23 | | |
IMGN632-0802, NCT04086264: IMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia |
|
|
| Active, not recruiting | 1/2 | 218 | Europe, US | Azacitidine, Vidaza, Decitabine, IMGN632, CD123-targeted ADC, Venetoclax, Venclexta, Venclyxto | ImmunoGen, Inc., Jazz Pharmaceuticals | Acute Myeloid Leukemia | 12/24 | 12/24 | | |
| Recruiting | 1 | 180 | Europe, Canada, US, RoW | ELVN-001 | Enliven Therapeutics | Chronic Myeloid Leukemia | 12/26 | 12/26 | | |
EPIK, NCT03481868: EPIgenetics and in Vivo Resistance of Chronic Myeloid Leukemia Stem Cells to Tyrosine Kinase Inhibitors |
|
|
| Recruiting | N/A | 160 | Europe | Collection of blood and bone marrow | University Hospital, Clermont-Ferrand, Institut Paoli-Calmettes, CHRU Lille, hematology department, CH Annecy Genevois, Institut Bergonié Bordeaux, hematology department, CHU Nancy, hematology department, CHU Saint-Etienne, hematology department, Institut Universitaire du Cancer de Toulouse - Oncopole, hematology department, CHU Caen, hematology department, CHU Nice, hematology department, CHU Lyon, hematology department, AP-HP, hematology department, AP-HP Hôpital Henri-Mondor, hematology department, Versailles Hospital, Centre Leon Berard, University Hospital, Grenoble | Chronic Myeloid Leukemia (CML), Chronic Phase | 05/25 | 02/26 | | |
BIO-TIMER, NCT06130787: Value of Biological Age, in Addition to Individual Frailty, for Personalising the Management of Cancer Treated with Targeted Therapy |
|
|
| Recruiting | N/A | 321 | Europe | Blood and bone marrow sample | University Hospital, Clermont-Ferrand | Leukemia,Myeloid, Chronic | 11/25 | 11/28 | | |
NCT05963061: Chronic Myeloid Leukemia (CML) Real-Life Database |
|
|
| Recruiting | N/A | 3500 | Europe | | University Hospital, Clermont-Ferrand, Centre Hospitalier Universitaire de Saint Etienne, Bicetre Hospital, University Hospital, Caen, Central Hospital, Nancy, France, University Hospital, Toulouse, CH Annecy Genevois, Rennes University Hospital, Hopital Paul Brousse, Versailles Hospital, Centre Hospitalier Emile Roux, University Hospital, Limoges, Institut Paoli-Calmettes, Centre Hospitalier de Rochefort | Chronic Myeloid Leukemia (CML) | 04/34 | 04/34 | | |
| Fenaux, Pierre |
| Recruiting | 3 | 124 | Europe | EPREX, Epoetin alfa | Groupe Francophone des Myelodysplasies | Myelodysplastic Syndromes | 05/22 | 05/24 | | |
| Recruiting | 3 | 550 | Europe, Canada, US, RoW | Tamibarotene, SY-1425, Placebo, Azacitidine | Syros Pharmaceuticals | Myelodysplastic Syndromes | 11/24 | 02/29 | | |
RIVER-81, NCT06191263: Safety and Efficacy of RVU120 Combined with Venetoclax for Treatment of Relapsed/Refractory AML |
|
|
| Recruiting | 2 | 98 | Europe | RVU120, SEL120, Venetoclax | Ryvu Therapeutics SA | Acute Myeloid Leukemia | 02/26 | 09/26 | | |
| Recruiting | 2 | 94 | Europe, Canada | RVU120, SEL120 | Ryvu Therapeutics SA | Acute Myeloid Leukemia (AML), High-risk Myelodysplastic Syndrome | 02/26 | 09/26 | | |
| Active, not recruiting | 2 | 57 | Europe | ASTX727, Donor Lymphocyte Infusions, DLI | Groupe Francophone des Myelodysplasies, Astex Pharmaceuticals, Inc. | MDS, AML | 04/24 | 04/25 | | |
| Active, not recruiting | 2 | 95 | Europe, US | Tamibarotene, Venetoclax, Venclexta, Azacitidine, Vidaza | Syros Pharmaceuticals | Acute Myeloid Leukemia | 04/28 | 04/28 | | |
NCT04827719: BST-236 as a Single Agent in Adults With Relapsed or Refractory AML or HR-MDS |
|
|
| Active, not recruiting | 2 | 40 | Europe | BST-236 | Groupe Francophone des Myelodysplasies | Myelodysplastic Syndromes, Acute Myeloid Leukemia | 04/25 | 04/25 | | |
SATISFY, NCT05935202: Safety and Efficacy of Mitapivat Sulfate in Adult Patients With Erythrocyte Membranopathies |
|
|
| Not yet recruiting | 2 | 25 | Europe | Mitapivat sulfate, AG-348 | EuroBloodNet Association | Hereditary Red Blood Cell Disorder (Disorder) | 07/25 | 12/26 | | |
AVENHIR, NCT05768711: Azacitidine Combined With Venetoclax in Patients With Higher-risk Chronic Myelomonocytic Leukemia |
|
|
| Recruiting | 2 | 44 | Europe | Venetoclax, ABT-199 | Groupe Francophone des Myelodysplasies, AbbVie | Chronic Myeloid Leukemia | 02/26 | 10/28 | | |
KCP-8602-801, NCT02649790: Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer Indications |
|
|
| Active, not recruiting | 1/2 | 277 | Europe, Canada, US, RoW | KPT-8602, Eltanexor, ASTX727, Dexamethasone | Karyopharm Therapeutics Inc | Relapsed/Refractory Multiple Myeloma (RRMM), Metastatic Colorectal Cancer (mCRC), Metastatic Castration-Resistant Prostate Cancer (mCRPC), Higher-Risk Myelodysplastic Syndrome (HR-MDS), Acute Myeloid Leukemia (AML), Newly Diagnosed Intermediate/High-Risk MDS | 08/24 | 12/24 | | |
|
| Recruiting | 1/2 | 55 | Europe | venetoclax + azacitidine +/- donor lymphocyte infusion, venclyxto, vidaza | Groupe Francophone des Myelodysplasies, AbbVie | MDS, AML | 09/25 | 03/26 | | |
NCT05782127: Oral Azacitidine Combined with Venetoclax in Previously Untreated Higher-risk Myelodysplastic Syndromes |
|
|
| Recruiting | 1/2 | 36 | Europe | Onureg + Venetoclax, CC-486 + ABT-199 | Groupe Francophone des Myelodysplasies, Bristol-Myers Squibb, AbbVie | Untreated Myelodysplastic Syndrome | 11/25 | 11/28 | | |
NCT02938858: French Registry of First-line Treatment of Acute Promyelocytic Leukemia |
|
|
| Recruiting | N/A | 400 | Europe | | Groupe Francophone des Myelodysplasies, Teva Pharmaceuticals USA | Acute Promyelocytic Leukemia | 10/20 | 10/22 | | |
NCT04174547: An European Platform for Translational Research in Myelodysplastic Syndromes |
|
|
| Recruiting | N/A | 8670 | Europe | | Istituto Clinico Humanitas | Myelodysplastic Syndromes | 09/21 | 09/22 | | |
| Recruiting | N/A | 37090 | Europe | Collection of clinical and laboratory data from EHR. | Hospital Universitari Vall d'Hebron Research Institute, ERN-EuroBloodNet (European Reference Network on Rare Hematological Diseases | Anemia, Bone Marrow Failure, Bleeding Disorder, Iron Metabolism Disorders, Myeloma, Lymphoid Neoplasm, Myeloma, Malignant, Leukemia, Anemia, Sickle Cell, Thalassemia, Blood Cancer, Red Cell Membrane and Enzyme Abnormalities | 07/37 | 07/37 | | |
| Active, not recruiting | N/A | 13284 | Europe | | Istituto Clinico Humanitas | Myelodysplastic Syndromes | 12/22 | 12/24 | | |
| BRIANDET, Claire |
| Recruiting | 3 | 800 | Europe, RoW | Vincristine, L01CA02, Carboplatin, LO1XA02, Etoposide, L01CB01, Vindesine, L01CA03, Dacarbazine, L01AX04, Ifosfamide, Doxorubicin, L01DB01, Busulfan, L01AB01, Melphalan, L01AA03, Thiotepa, L01AC01, Radiotherapy, Dinutuximab Beta, L01XC16, Cisplatin, L01XA01, Temozolomide 100 MG, Irinotecan, Cyclophosphamid | Gustave Roussy, Cancer Campus, Grand Paris, PHRC, Solving Kids' Cancer Europe, Neuroblastoma UK, , BSPHO, Instituto de Investigación Sanitaria La Fe, Deutsche Krebshilfe | High-Risk Neuroblastoma, Patient With Insufficient Response Chemoimmunotherapy | 11/26 | 11/32 | | |
| Recruiting | 3 | 409 | Europe | Everolimus, VOTUBIA, AFINITOR, ONC201, Radiotherapy | Gustave Roussy, Cancer Campus, Grand Paris, Chimerix, Innovative Therapies For Children with Cancer Consortium, Ministry of Health, France | Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, H3 K27M-Mutant | 09/28 | 09/31 | | |
| Recruiting | 2/3 | 536 | Europe, RoW | 16 weeks of VEC + CDDP, Vincristine, Etoposide, Cyclophosphamide, Cisplatin, VEC + HD-MTX, Methotrexate, Chemotherapy + Valproate, Carboplatin, Valproate, Conformal radiotherapy, VEC, Chemotherapy, conformal radiotherapy +/- boost | Centre Leon Berard | Childhood Ependymoma | 06/28 | 08/31 | | |
RETINO2018, NCT04681417: Ocular Conservative Treatment for Retinoblastoma : Efficacy of the New Management Strategies and Visual Outcome |
|
|
| Recruiting | 2/3 | 225 | Europe | Melphalan or Melphalan + Topotecan, Alkeran, Topotecan Accord; Topotecan Hospira chemotherapy, etoposide, carboplatin and vincristine or local ophthalmological treatment without IV chemotherapy, etoposide, carboplatin and vincristine chemotherapy, Carboplatin administered on Day 1, platinum-based chemotherapy, Thermotherapy (local treatment), Thermotherapy after carboplatin administered on Day 1, Cryotherapy (local treatment), Iodine-125 plaques (local treatment), Intravitreal Melphalan chemotherapy injections (local treatment) | Institut Curie, Fondation Rothschild Paris | Retinoblastoma | 01/35 | 01/36 | | |
| Active, not recruiting | 2 | 133 | Europe | VP16, carboplatin, etoposide, vepesid, chemotherapy, Melphalan, Alkeran, chemotherapy, VP16, carboplatin, vincristin, etoposide, vepesid, leurocristine, Oncovin, chemotherapy, Carboplatin + laser day 1 (chemothermotherapy), Carbo-laser, platinum-based chemotherapy, Laser (local treatment), Laser diode, cryoapplication (local treatment), I125 radioactive plaques (local treatment), intravitreal Melphalan (local treatment) | Institut Curie, Fondation Rothschild Paris | Retinoblastoma, Children, Retinal Neoplasm | 01/23 | 09/35 | | |
| Recruiting | 2 | 185 | Europe | Observation, Low risk group, Etoposide, Intermediate risk sub group 1, Vincristine, Intermediate risk sub group 2, Orbital irradiation, High risk group, Carboplatin, Cyclophosphamide, Thiotepa, Cytapheresis, Peripheral bood stem cell transplantation | Institut Curie | Retinoblastoma | 03/30 | 09/30 | | |
NCT03306251: National Cohort of Children Born to HIV-positive Mothers |
|
|
| Recruiting | N/A | 5200 | Europe, RoW | | ANRS, Emerging Infectious Diseases | Mother to Child Transmission of HIV | 03/23 | 03/23 | | |
SACHA, NCT04477681: Securing Access to Innovative Molecules in Oncology and Hematology for Children, Adolescents and Young Adults |
|
|
| Recruiting | N/A | 750 | Europe | Data collection | Gustave Roussy, Cancer Campus, Grand Paris, Société Française des Cancers de l'Enfant (SFCE) | Pediatric Cancer | 04/25 | 04/26 | | |
MICCHADO, NCT03496402: Biological Characterisation of High Risk CHildhood Cancer in Children, Adolescents and Young Adults |
|
|
| Recruiting | N/A | 600 | Europe | Sampling on blood, bone marrow and cerebrospinal fluid | Institut Curie | Neuroblastoma, Rhabdomyosarcoma, Ewing Sarcoma Family of Tumors, Osteosarcoma, Leukemia, Central Nervous System Tumor | 04/27 | 08/27 | | |
BIOPORTAL, NCT05192980: SIOPEN , An International Registry Linked to a Virtual Biobank for Patients With Peripheral Neuroblastic Tumours |
|
|
| Recruiting | N/A | 600 | Europe | No Intervention NA, Bio-sampling | Institut Curie | Neuroblastoma, Ganglioneuroblastoma, Ganglioneuroma | 11/38 | 11/38 | | |
| Recruiting | N/A | 40 | Europe | | University Hospital, Strasbourg, France | Primary Brain Tumor | 12/23 | 12/23 | | |
| RAFFOUX, Emmanuel |
| Recruiting | 3 | 322 | Europe, Canada, US | Crenolanib, Crenolanib besylate, Cytarabine, Mitoxantrone, Placebo Oral Tablet, Fludarabine, Idarubicin, G-CSF | Arog Pharmaceuticals, Inc. | Relapsed/Refractory Acute Myeloid Leukemia With FLT3 Activating Mutations | 10/24 | 10/24 | | |
BIG-1, NCT02416388: Study to Improve OS in 18 to 60 Year-old Patients, Comparing Daunorubicin Versus High Dose Idarubicin Induction Regimens, High Dose Versus Intermediate Dose Cytarabine Consolidation Regimens, and Standard Versus MMF Prophylaxis of GvHD in Allografted Patients in First CR |
|
|
| Recruiting | 2/3 | 3100 | Europe | Idarubicin, Daunorubicin, HD Cytarabine, Cyclosporine, Methotrexate, Mycophenolic acid (MPA), vosaroxin, ID cytarabine, Dexamethasone, Venetoclax | University Hospital, Angers | Acute Myeloid Leukemia (AML) | 07/25 | 01/32 | | |
PONAZA, NCT03895671: : A COMBINATION OF PONATINIB AND 5-AZACITIDINE IN CHRONIC MYELOGENOUS LEUKAEMIA IN ACCELERATED PHASE OR IN MYELOID BLAST CRISIS |
|
|
| Recruiting | 2 | 40 | Europe | Ponatinib, Azacitidine | Versailles Hospital | CHRONIC MYELOGENOUS LEUKAEMIA IN ACCELERATED PHASE, CHRONIC MYELOGENOUS LEUKAEMIA IN MYELOID BLAST CRISIS | 12/23 | 12/24 | | |
OGILAR, NCT06022003: Study Investigating the Efficacy and Safety of the Addition of Oral-azacitidine to Salvage Treatment by Gilteritinib in Subjects ≥18 Years of Age With Relapsed/Refractory FLT3-mutated Acute Myeloid Leukemia |
|
|
| Recruiting | 2 | 33 | Europe | AzaCITIDine Oral Tablet, Onureg, CC-486, Xospata, Gilteritinib | French Innovative Leukemia Organisation, Acute Leukemia French Association | AML, Adult, Refractory AML, Relapsed Adult AML, FLT3-TKD Mutation, FLT3-ITD | 10/25 | 04/26 | | |
AGORA-1, NCT05199051: A Phase 2 Study of Gemtuzumab Ozogamicin (GO)-Gilteritinib Combination in Adults With FLT3-ITD Relapse/Refractory (R/R) AML |
|
|
| Recruiting | 2 | 50 | Europe | Gemtuzumab ozogamicine - Cytarabine - Gilteritinib, Mylotarg - Aracytine - Xospata | Centre Antoine Lacassagne, Acute Leukemia French Association | AML | 03/27 | 03/27 | | |
| Recruiting | 1/2 | 413 | Europe, Canada, US, RoW | revumenib, SNDX-5613, cobicistat | Syndax Pharmaceuticals, Syndax Pharmaceuticals, Inc | Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Mixed Lineage Acute Leukemia, Mixed Phenotype Acute Leukemia, Acute Leukemia of Ambiguous Lineage | 12/24 | 12/24 | | |
|
|
|
|
|
|
|
|
|
| Recruiting | 1/2 | 70 | Europe, Canada, Japan, US, RoW | DSP-5336 | Sumitomo Pharma America, Inc. | Leukemia, Myeloid, Acute, Leukemia, Lymphocytic, Acute | 01/25 | 02/25 | | |
VENAZA, NCT06263387: Results From a French Temporary Utilization Authorization of First-line Acute Myeloid Leukemia (AML) Patients Ineligible for Intensive Chemotherapy (IC), Treated With Venetoclax Azacitidine |
|
|
| Recruiting | N/A | 230 | Europe | | French Innovative Leukemia Organisation, Acute Leukemia French Association | AML, Adult | 12/24 | 03/25 | | |
NCT06377579: OBServatory of Compassionate Use of IVOsidenib in France for Patients with Acute Myeloid Leukemia |
|
|
| Recruiting | N/A | 250 | Europe | | French Innovative Leukemia Organisation, Acute Leukemia French Association | AML, Adult | 12/24 | 03/25 | | |
| ADES, Lionel |
| Active, not recruiting | 2 | 68 | Europe | AG-221, Enasidenib | Groupe Francophone des Myelodysplasies | Myelodysplastic Syndromes, Leukemia Acute Myeloid | 02/23 | 03/26 | | |
| Recruiting | 2 | 140 | Europe, US, RoW | KER-050 | Keros Therapeutics, Inc. | Myelodysplastic Syndromes, Cytopenia | 06/25 | 11/25 | | |
|
| Recruiting | 1/2 | 199 | Europe, Canada, US | Ziftomenib | Kura Oncology, Inc. | Advanced Malignant Neoplasm, Acute Myeloid Leukemia, Mixed Lineage Leukemia, Mixed Lineage Acute Leukemia, Acute Leukemia of Ambiguous Lineage, Mixed Phenotype Acute Leukemia | 09/24 | 09/25 | | |
NCT05181735: Study Evaluating Combination of Luspatercept in LR-MDS Without RS Having Failed or Being Ineligible to ESA |
|
|
| Recruiting | 1/2 | 150 | Europe | Luspatercept Injection [Reblozyl], ACE-536, Eprex, Epoietin alfa | Groupe Francophone des Myelodysplasies, Celgene | MDS, Myelodysplastic Syndromes | 05/27 | 11/27 | | |
| Vey, Norbert |
| Recruiting | 3 | 124 | Europe | EPREX, Epoetin alfa | Groupe Francophone des Myelodysplasies | Myelodysplastic Syndromes | 05/22 | 05/24 | | |
| Recruiting | 3 | 322 | Europe, Canada, US | Crenolanib, Crenolanib besylate, Cytarabine, Mitoxantrone, Placebo Oral Tablet, Fludarabine, Idarubicin, G-CSF | Arog Pharmaceuticals, Inc. | Relapsed/Refractory Acute Myeloid Leukemia With FLT3 Activating Mutations | 10/24 | 10/24 | | |
| Recruiting | 3 | 142 | Europe | Dexamethasone, Amsacrine, Cytarabine, Azacitidine | University Hospital, Toulouse | Relapsed or Refractory Acute Myeloid Leukemia | 12/25 | 12/25 | | |
BIG-1, NCT02416388: Study to Improve OS in 18 to 60 Year-old Patients, Comparing Daunorubicin Versus High Dose Idarubicin Induction Regimens, High Dose Versus Intermediate Dose Cytarabine Consolidation Regimens, and Standard Versus MMF Prophylaxis of GvHD in Allografted Patients in First CR |
|
|
| Recruiting | 2/3 | 3100 | Europe | Idarubicin, Daunorubicin, HD Cytarabine, Cyclosporine, Methotrexate, Mycophenolic acid (MPA), vosaroxin, ID cytarabine, Dexamethasone, Venetoclax | University Hospital, Angers | Acute Myeloid Leukemia (AML) | 07/25 | 01/32 | | |
| Active, not recruiting | 2 | 68 | Europe | AG-221, Enasidenib | Groupe Francophone des Myelodysplasies | Myelodysplastic Syndromes, Leukemia Acute Myeloid | 02/23 | 03/26 | | |
| Active, not recruiting | 2 | 68 | Europe | AG-120 | Groupe Francophone des Myelodysplasies | Myelodysplastic Syndromes, Acute Myeloid Leukemia | 04/25 | 04/25 | | |
AVENHIR, NCT05768711: Azacitidine Combined With Venetoclax in Patients With Higher-risk Chronic Myelomonocytic Leukemia |
|
|
| Recruiting | 2 | 44 | Europe | Venetoclax, ABT-199 | Groupe Francophone des Myelodysplasies, AbbVie | Chronic Myeloid Leukemia | 02/26 | 10/28 | | |
